Summit Trail Advisors LLC boosted its holdings in shares of Abbott Laboratories (NYSE:ABT) by 18.9% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 18,403 shares of the healthcare product maker’s stock after buying an additional 2,923 shares during the period. Summit Trail Advisors LLC’s holdings in Abbott Laboratories were worth $769,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of ABT. Icon Wealth Partners LLC bought a new stake in Abbott Laboratories during the fourth quarter worth about $102,000. SWS Partners bought a new stake in Abbott Laboratories during the fourth quarter worth about $104,000. Rainier Group Investment Advisory LLC bought a new stake in Abbott Laboratories during the first quarter worth about $114,000. Private Ocean LLC lifted its stake in Abbott Laboratories by 9,868.2% during the first quarter. Private Ocean LLC now owns 2,193 shares of the healthcare product maker’s stock worth $131,000 after purchasing an additional 2,171 shares during the last quarter. Finally, We Are One Seven LLC bought a new stake in Abbott Laboratories during the fourth quarter worth about $138,000. 71.67% of the stock is owned by institutional investors.

In related news, insider Daniel Gesua Sive Salvadori sold 3,000 shares of the business’s stock in a transaction dated Friday, May 18th. The stock was sold at an average price of $61.20, for a total transaction of $183,600.00. Following the transaction, the insider now owns 95,581 shares in the company, valued at approximately $5,849,557.20. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Jaime Contreras sold 849 shares of the business’s stock in a transaction dated Monday, April 23rd. The shares were sold at an average price of $59.36, for a total value of $50,396.64. Following the transaction, the insider now owns 50,436 shares in the company, valued at approximately $2,993,880.96. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,999 shares of company stock worth $359,901. 0.74% of the stock is owned by company insiders.

Several equities research analysts have issued reports on the company. Sanford C. Bernstein assumed coverage on Abbott Laboratories in a research note on Wednesday, June 27th. They set an “outperform” rating and a $73.00 price target for the company. Citigroup dropped their price target on Abbott Laboratories from $66.00 to $65.00 and set a “neutral” rating for the company in a research note on Tuesday, April 24th. BTIG Research reaffirmed a “hold” rating on shares of Abbott Laboratories in a research note on Sunday, April 22nd. Finally, Zacks Investment Research raised Abbott Laboratories from a “hold” rating to a “buy” rating and set a $67.00 price target for the company in a research note on Friday, April 20th. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Abbott Laboratories has an average rating of “Buy” and a consensus target price of $69.35.

Abbott Laboratories opened at $60.81 on Wednesday, according to Marketbeat Ratings. The stock has a market capitalization of $106.94 billion, a PE ratio of 23.37, a P/E/G ratio of 1.77 and a beta of 1.50. The company has a current ratio of 1.66, a quick ratio of 1.24 and a debt-to-equity ratio of 0.67. Abbott Laboratories has a 12 month low of $47.83 and a 12 month high of $64.60.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, April 18th. The healthcare product maker reported $0.59 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.58 by $0.01. The firm had revenue of $7.39 billion for the quarter, compared to the consensus estimate of $7.28 billion. Abbott Laboratories had a return on equity of 14.54% and a net margin of 1.67%. The company’s quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.48 earnings per share. analysts predict that Abbott Laboratories will post 2.86 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 15th. Stockholders of record on Friday, July 13th will be issued a $0.28 dividend. The ex-dividend date of this dividend is Thursday, July 12th. This represents a $1.12 annualized dividend and a dividend yield of 1.84%. Abbott Laboratories’s dividend payout ratio is currently 44.80%.

Abbott Laboratories Profile

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon.

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.